A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas

Trial Profile

A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Romidepsin (Primary) ; Dexamethasone; Gemcitabine; Oxaliplatin; Pegfilgrastim
  • Indications Diffuse large B cell lymphoma; Hodgkin's disease; Mycosis fungoides; Sezary syndrome; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2017 Planned number of patients changed from 27 to 24.
    • 28 Sep 2017 Planned End Date changed from 30 Apr 2019 to 31 Dec 2019.
    • 28 Sep 2017 Planned primary completion date changed from 31 Oct 2017 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top